JP2012530496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530496A5 JP2012530496A5 JP2012516307A JP2012516307A JP2012530496A5 JP 2012530496 A5 JP2012530496 A5 JP 2012530496A5 JP 2012516307 A JP2012516307 A JP 2012516307A JP 2012516307 A JP2012516307 A JP 2012516307A JP 2012530496 A5 JP2012530496 A5 JP 2012530496A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- antibody
- binding fragment
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010045030 monoclonal antibodies Proteins 0.000 claims 17
- 102000005614 monoclonal antibodies Human genes 0.000 claims 17
- 230000000875 corresponding Effects 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 102000004965 antibodies Human genes 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 239000000611 antibody drug conjugate Substances 0.000 claims 5
- 108091008116 antibody drug conjugates Proteins 0.000 claims 5
- 102220250290 rs1554074673 Human genes 0.000 claims 4
- 108010005144 Bevacizumab Proteins 0.000 claims 3
- 102220398847 METTL15 H97E Human genes 0.000 claims 3
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 3
- 108010062724 Ranibizumab Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001394 metastastic Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102220344151 rs1287146448 Human genes 0.000 claims 3
- 102200058908 ANG K64Q Human genes 0.000 claims 2
- 206010021425 Immune system disease Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 1
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 1
- 102100014838 FCGRT Human genes 0.000 claims 1
- 101710003435 FCGRT Proteins 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 102200092453 HEPH Y98F Human genes 0.000 claims 1
- 102200034855 LIMCH1 Y53F Human genes 0.000 claims 1
- 102220442983 MTR K64S Human genes 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
Claims (17)
- モノクローナル抗体又はその結合フラグメントであって、
（ａ）ヒトＶＥＧＦに特異的に結合し；
（ｂ）ヒトＶＥＧＦへの結合に関して、
ｉ．配列番号１のＶＨ配列及び配列番号２のＶＬ配列、又は
ｉｉ．配列番号９のＶＨ配列及び配列番号１０のＶＬ配列
を含む抗体と競合し；
（ｃ）配列番号３又は配列番号１１（ＣＤＲ−Ｈ１）、配列番号４（ＣＤＲ−Ｈ２）、配列番号５又は配列番号１２（ＣＤＲ−Ｈ３）、配列番号６（ＣＤＲ−Ｌ１）、配列番号７（ＣＤＲ−Ｌ２）、及び配列番号８（ＣＤＲ−Ｌ３）と比較して合計１０個までのアミノ酸置換を有する６個のＣＤＲを含み；
（ｄ）以下：
ｉ）ＣＤＲ−Ｈ２におけるＫ６４Ｓ；
ｉｉ）ＣＤＲ−Ｈ２におけるＫ６４Ｑ；
ｉｉｉ）ＣＤＲ−Ｈ２におけるＹ５３Ｆ及びＫ６４Ｑ；
ｉｖ）ＣＤＲ−Ｈ３におけるＨ９７Ｅ及びＹ９８Ｆ；
ｖ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＨ９７Ｄと、ＣＤＲ−Ｈ３におけるＹ９９Ｄと、ＣＤＲ−Ｈ３におけるＳ１００ａＧ；
ｖｉ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＨ９７Ｐと、ＣＤＲ−Ｈ３におけるＹ９９Ｄと、ＣＤＲ−Ｈ３におけるＳ１００ａＧ；
ｖｉｉ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＨ９７Ｐと、ＣＤＲ−Ｈ３におけるＹ９９Ｅ；
ｖｉｉｉ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＨ９７Ｅと、ＣＤＲ−Ｈ３におけるＹ９９Ｅ；
ｉｘ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＨ９７Ｄと、ＣＤＲ−Ｈ３におけるＹ９９Ｅ；
ｘ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＨ９７Ｅと、ＣＤＲ−Ｈ３におけるＹ９９Ｄと、ＣＤＲ−Ｈ３におけるＳ１００ａＧ；
ｘｉ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＹ９９Ｄと、ＣＤＲ−Ｈ３におけるＳ１００ａＧ；
ｘｉｉ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＨ９７Ｐと、ＣＤＲ−Ｈ３におけるＹ９９Ｄ；
ｘｉｉｉ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＨ９７Ｄと、ＣＤＲ−Ｈ３におけるＳ１００ａＧ；
ｘｉｖ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＳ１００ａＧ；及び
ｘｖ）ＣＤＲ−Ｈ１におけるＮ３１Ｆと、ＣＤＲ−Ｈ３におけるＨ９７Ｐと、ＣＤＲ−Ｈ３におけるＳ１００ａＧ
から選択される少なくとも１つのアミノ酸置換又はアミノ酸置換の組合せを有し；並びに
（ｅ）場合により、下記に示す表６、表７、表８、表９、表１０、表１１、表１２−１〜表１２−９、或いは表１３〜表１６の１以上から選択される１種以上の他の突然変異もしくは突然変異の組合せを有する
- ｉ）からｘｖ）から選択される置換組合せ以外に、重鎖ＣＤＲが抗体ベバシズマブの重鎖ＣＤＲ配列又は抗体ラニビズマブの重鎖ＣＤＲ配列に比較して他の突然変異を含まない、請求項１に記載のモノクローナル抗体又はその結合フラグメント。
- ａ）６個のＣＤＲが抗体ベバシズマブ又は抗体ラニビズマブのＣＤＲ配列に比較して合計９カ所まで、８カ所まで、７カ所まで、６カ所まで、５カ所まで又は４カ所までのアミノ酸置換を有する；及び／又は
ｂ）任意の個別のＣＤＲが抗体ベバシズマブ又は抗体ラニビズマブの対応するＣＤＲ配列に比較して２カ所以下の又は３カ所以下のアミノ酸置換を有する、
請求項１又は２に記載のモノクローナル抗体又はその結合フラグメント。 - 夫々ヒトもしくはヒト化抗体、又はヒトもしくはヒト化抗体の抗ＶＥＧＦ結合フラグメントである、請求項１〜３のいずれか一項に記載のモノクローナル抗体又はその結合フラグメント。
- ＩｇＧ、例えばＩｇＧ１又はＩｇＧ２である、請求項１〜４のいずれか一項に記載のモノクローナル抗体又はその結合フラグメント。
- ａ）ＡＤＣＣ活性を増加する１種以上の突然変異をＦｃ領域に含む；
ｂ）フコシル化されていない；及び／又は
ｃ）ＦｃγＲとの結合性を増加する又はＦｃＲｎとの結合性を増加するのいずれかである１種以上の突然変異をＦｃ領域に含む、
請求項１〜５のいずれか一項に記載のモノクローナル抗体又はその結合フラグメント。 - ＡＤＣＣ活性を低下させる１種以上の突然変異をＦｃ領域に含む、請求項１〜５のいずれか一項に記載のモノクローナル抗体又はその結合フラグメント。
- （ａ）前記１種以上の突然変異以外に、配列番号１に対応するＶＨ配列及び配列番号２に対応するＶＬ配列を有する；
（ｂ）前記１種以上の突然変異以外に、配列番号９に対応する重鎖配列及び配列番号１０に対応する軽鎖配列を有する；
（ｃ）配列番号１に対応するＶＨ配列及び配列番号２に対応するＶＬ配列をもつ抗体の親和性の１．５から５０倍の、又は２から３０倍の親和性を有する；又は
（ｄ）配列番号９に対応する重鎖配列及び配列番号１０に対応する軽鎖配列をもつ抗体の親和性の１．５から５０倍の、又は２から３０倍の親和性を有し；
場合により、親和性がバイオセンサーにより分析されるＫＤの測定である、
請求項１〜７のいずれか一項に記載のモノクローナル抗体又はその結合フラグメント。 - 例えば、少なくとも８５％、少なくとも９０％、少なくとも９５％又は少なくとも９８％の均一性まで精製されている、請求項１〜８のいずれか一項に記載のモノクローナル抗体又はその結合フラグメント。
- 請求項１〜９のいずれか一項に記載のモノクローナル抗体又はその結合フラグメントを含む、抗体−薬剤コンジュゲート。
- 請求項１〜９のいずれか一項に記載のモノクローナル抗体又はその結合フラグメント、或いは請求項１０に記載の抗体−薬剤コンジュゲートと、医薬的に許容可能な担体と、を含む医薬組成物。
- 請求項１〜８のいずれか一項に記載のモノクローナル抗体又はその結合フラグメントをコードするヌクレオチド配列を含む核酸。
- 請求項１２に記載の核酸を含むベクター。
- 請求項１３に記載のベクターで形質転換された原核宿主細胞もしくは真核宿主細胞、或いは請求項１２に記載のヌクレオチド配列を発現するように遺伝子組換えされた真核宿主細胞であって、
場合により、遺伝子組換えされた真核宿主細胞が哺乳動物宿主細胞である、宿主細胞。 - （ａ）請求項１４に記載の真核宿主細胞を培養すること；及び
（ｂ）モノクローナル抗体又はその結合フラグメントを回収すること
を含む、モノクローナル抗体又はその結合フラグメントの作製方法。 - 癌を治療するための医薬の製造における、請求項１〜９のいずれか一項に記載のモノクローナル抗体又はその結合フラグメント、請求項１０に記載の抗体−薬剤コンジュゲート、又は請求項１１に記載の医薬組成物の使用であって、
場合により、癌が転移性結腸癌、転移性直腸癌、非扁平上皮型非小細胞肺癌又は転移性ＨＥＲ２陰性乳癌であり、さらに場合により癌が切除不能、局所進行、再発性又は転移性の非扁平上皮型非小細胞肺癌である、前記使用。 - 加齢黄斑変性又は免疫疾患を治療するための医薬の製造における、請求項１〜９のいずれか一項に記載のモノクローナル抗体又はその結合フラグメント、請求項１０に記載の抗体−薬剤コンジュゲート、又は請求項１１に記載の医薬組成物の使用であって、
場合により、免疫疾患が関節リウマチ又はグレーブス病である、前記使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21800509P | 2009-06-17 | 2009-06-17 | |
| US61/218,005 | 2009-06-17 | ||
| PCT/US2010/039029 WO2010148223A2 (en) | 2009-06-17 | 2010-06-17 | Anti-vegf antibodies and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530496A JP2012530496A (ja) | 2012-12-06 |
| JP2012530496A5 true JP2012530496A5 (ja) | 2013-08-01 |
| JP5785941B2 JP5785941B2 (ja) | 2015-09-30 |
Family
ID=42543312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516307A Expired - Fee Related JP5785941B2 (ja) | 2009-06-17 | 2010-06-17 | 抗ｖｅｇｆ抗体とその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9079953B2 (ja) |
| EP (2) | EP2894167B1 (ja) |
| JP (1) | JP5785941B2 (ja) |
| KR (1) | KR20120034739A (ja) |
| CN (1) | CN102482349B (ja) |
| AU (1) | AU2010262836B2 (ja) |
| BR (1) | BRPI1012321A8 (ja) |
| CA (1) | CA2765755C (ja) |
| CL (1) | CL2011003182A1 (ja) |
| CO (1) | CO6480962A2 (ja) |
| CR (1) | CR20110653A (ja) |
| EC (1) | ECSP12011584A (ja) |
| ES (2) | ES2534355T3 (ja) |
| GT (1) | GT201100326A (ja) |
| HK (1) | HK1211961A1 (ja) |
| IL (2) | IL216835A0 (ja) |
| MX (2) | MX2011013781A (ja) |
| NZ (1) | NZ596837A (ja) |
| PE (1) | PE20120622A1 (ja) |
| RU (1) | RU2567639C2 (ja) |
| SG (2) | SG177265A1 (ja) |
| TW (1) | TWI510248B (ja) |
| UA (1) | UA104626C2 (ja) |
| WO (1) | WO2010148223A2 (ja) |
| ZA (1) | ZA201109098B (ja) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| JP2014505698A (ja) * | 2011-02-02 | 2014-03-06 | グラクソ グループ リミテッド | 新規抗原結合タンパク質 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CA2833176C (en) | 2011-04-12 | 2023-05-16 | C.B. Appaiah | Chimeric antibacterial polypeptides |
| IN2014DN11157A (ja) | 2012-07-13 | 2015-10-02 | Roche Glycart Ag | |
| CN104662161A (zh) * | 2012-09-19 | 2015-05-27 | 弗·哈夫曼-拉罗切有限公司 | 用于防止正亮氨酸错误地掺入蛋白质中的方法和组合物 |
| WO2014052713A2 (en) | 2012-09-27 | 2014-04-03 | Massachusetts Institute Of Technology | Her2-and vegf-a-binding proteins with enhanced stability |
| KR101279895B1 (ko) * | 2012-10-24 | 2013-06-28 | 주식회사 진흥기공 | 유체 이송용 덕트에 결합 사용되는 댐퍼의 이중 브레이드 밀폐 장치 |
| US20140154255A1 (en) * | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| CN105188749B (zh) | 2012-12-21 | 2017-12-19 | 西雅图基因公司 | 抗ntb‑a抗体及相关组合物和方法 |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| WO2014178078A2 (en) * | 2013-04-30 | 2014-11-06 | Intas Boipharmaceuticals Limited | Novel cloning, expression & purification method for the preparation of ranibizumab |
| EA201690212A8 (ru) * | 2013-07-12 | 2016-08-31 | Офтотек Корпорейшн | Способы лечения или профилактики офтальмологических патологических состояний |
| ES2819217T3 (es) | 2013-09-08 | 2021-04-15 | Kodiak Sciences Inc | Conjugados de polímeros iónicos dipolares y factor VIII |
| JP6983511B2 (ja) | 2014-04-25 | 2021-12-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脳中の転移乳癌および他の癌を処置するための方法および組成物 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI719939B (zh) * | 2014-07-14 | 2021-03-01 | 日商中外製藥股份有限公司 | 鑑定蛋白質抗原決定位之方法 |
| WO2016061562A2 (en) | 2014-10-17 | 2016-04-21 | Kodiak Sciences Inc. | Butyrylcholinesterase zwitterionic polymer conjugates |
| CN108148135B (zh) * | 2015-01-06 | 2020-06-12 | 珠海亿胜生物制药有限公司 | 抗vegf抗体 |
| JP7088454B2 (ja) * | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| EP3452103A1 (en) * | 2016-04-15 | 2019-03-13 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| JP2019515027A (ja) * | 2016-04-15 | 2019-06-06 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| CN106039309B (zh) * | 2016-06-30 | 2024-04-19 | 中国人民解放军总医院第一附属医院 | 用于治疗恶性肿瘤造成的胸腔积液的药物组合物及其应用 |
| RU2656160C2 (ru) | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
| WO2019126329A1 (en) * | 2017-12-19 | 2019-06-27 | Akouos Llc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| JP2022512657A (ja) * | 2018-10-12 | 2022-02-07 | トリカン・バイオテクノロジー・カンパニー・リミテッド | 二機能性融合タンパク質およびその使用 |
| CN111423512B (zh) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN111363038A (zh) * | 2020-03-26 | 2020-07-03 | 北京纽安博生物技术有限公司 | 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用 |
| CN111808191A (zh) * | 2020-05-11 | 2020-10-23 | 廊坊天光生物技术有限公司 | 一种用于检测血清中vegf含量的抗体对及其用途 |
| WO2022119839A1 (en) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| CN116897052A (zh) * | 2021-03-04 | 2023-10-17 | 百奥泰生物制药股份有限公司 | 抗vegf抗体制剂 |
| WO2023150142A1 (en) | 2022-02-02 | 2023-08-10 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| PT1787999E (pt) * | 1997-04-07 | 2010-11-11 | Genentech Inc | Anticorpos anti-vegf |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US20070059302A1 (en) * | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| RU2224766C2 (ru) | 1997-04-14 | 2004-02-27 | Микромет Аг | Способ получения рецепторов для человеческих антигенов и их применение |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP1950300A3 (en) | 1998-11-18 | 2011-03-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| ATE384792T1 (de) | 1998-11-18 | 2008-02-15 | Genentech Inc | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern |
| EP2016953A3 (en) * | 1998-12-22 | 2009-04-15 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
| US6979559B2 (en) * | 2000-10-12 | 2005-12-27 | Marical, Inc. | Polyvalent cation-sensing receptor in atlantic salmon |
| EP1356052B1 (en) | 2000-12-14 | 2008-08-20 | Genentech, Inc. | Production of full antibodies in procaryotic cells |
| BR0116680A (pt) * | 2000-12-14 | 2005-04-05 | Genentech Inc | Linhagem de e. coli e método de produção de um polipeptìdeo |
| US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
| CA2369893A1 (en) | 2001-02-12 | 2002-08-12 | Warner-Lambert Company | Vegf responsive cell-based assay for determining vegf bioactivity |
| US20040010376A1 (en) * | 2001-04-17 | 2004-01-15 | Peizhi Luo | Generation and selection of protein library in silico |
| US7117096B2 (en) * | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20030022240A1 (en) * | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| JP2006506943A (ja) | 2002-02-11 | 2006-03-02 | ジェネンテック・インコーポレーテッド | 抗原結合速度の大きい抗体変異体 |
| WO2003099999A2 (en) | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003287345A1 (en) * | 2002-10-31 | 2004-06-07 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| AU2004205684A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| ZA200509059B (en) * | 2003-05-30 | 2007-01-31 | Genentech Inc | Treatment with anti-VEGF antibodies |
| EP3722309A1 (en) * | 2003-07-28 | 2020-10-14 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| AU2005285347A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20080292628A1 (en) * | 2004-10-12 | 2008-11-27 | Amprotein Corporation | Chimeric Protein |
| NZ554481A (en) | 2004-10-12 | 2010-04-30 | Amprotein Corp | Fusion protein that binds to IL-1 receptor and one of IL18, IL4 or IL13 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US20080207467A1 (en) * | 2005-03-03 | 2008-08-28 | Xencor, Inc. | Methods for the design of libraries of protein variants |
| EP1966374B1 (en) * | 2005-11-14 | 2013-02-13 | Bioren, Inc. | Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening |
| WO2007059336A1 (en) | 2005-11-18 | 2007-05-24 | Nextrom Oy | Method and apparatus for manufacturing water-free optical fiber preforms |
| CA2627446A1 (en) * | 2005-11-21 | 2007-05-31 | Laboratoires Serono S.A. | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| KR101535678B1 (ko) * | 2006-01-23 | 2015-07-09 | 조셉 피. 에리코 | 표적 약물 개발의 방법 및 조성물 |
| CN101505794B (zh) * | 2006-07-10 | 2013-09-04 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 穿过上皮和/或内皮层的scFV抗体 |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| SG10202005450PA (en) * | 2007-07-09 | 2020-07-29 | Genentech Inc | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| US8314213B2 (en) * | 2008-04-18 | 2012-11-20 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
-
2010
- 2010-06-17 CA CA2765755A patent/CA2765755C/en not_active Expired - Fee Related
- 2010-06-17 RU RU2011150916/10A patent/RU2567639C2/ru not_active IP Right Cessation
- 2010-06-17 EP EP14197237.2A patent/EP2894167B1/en not_active Not-in-force
- 2010-06-17 MX MX2011013781A patent/MX2011013781A/es active IP Right Grant
- 2010-06-17 CN CN201080027121.5A patent/CN102482349B/zh not_active Expired - Fee Related
- 2010-06-17 KR KR1020127001157A patent/KR20120034739A/ko not_active Application Discontinuation
- 2010-06-17 US US12/817,800 patent/US9079953B2/en not_active Expired - Fee Related
- 2010-06-17 MX MX2014001638A patent/MX346002B/es unknown
- 2010-06-17 NZ NZ596837A patent/NZ596837A/en not_active IP Right Cessation
- 2010-06-17 AU AU2010262836A patent/AU2010262836B2/en not_active Ceased
- 2010-06-17 SG SG2011093473A patent/SG177265A1/en unknown
- 2010-06-17 EP EP10725590.3A patent/EP2443150B1/en active Active
- 2010-06-17 TW TW099119749A patent/TWI510248B/zh not_active IP Right Cessation
- 2010-06-17 PE PE2011002096A patent/PE20120622A1/es not_active Application Discontinuation
- 2010-06-17 SG SG10201403327WA patent/SG10201403327WA/en unknown
- 2010-06-17 BR BRPI1012321A patent/BRPI1012321A8/pt not_active IP Right Cessation
- 2010-06-17 JP JP2012516307A patent/JP5785941B2/ja not_active Expired - Fee Related
- 2010-06-17 ES ES10725590.3T patent/ES2534355T3/es active Active
- 2010-06-17 ES ES14197237.2T patent/ES2656446T3/es active Active
- 2010-06-17 WO PCT/US2010/039029 patent/WO2010148223A2/en active Application Filing
- 2010-06-17 UA UAA201114515A patent/UA104626C2/ru unknown
-
2011
- 2011-12-06 CR CR20110653A patent/CR20110653A/es unknown
- 2011-12-07 IL IL216835A patent/IL216835A0/en not_active IP Right Cessation
- 2011-12-09 ZA ZA2011/09098A patent/ZA201109098B/en unknown
- 2011-12-15 CL CL2011003182A patent/CL2011003182A1/es unknown
- 2011-12-16 GT GT201100326A patent/GT201100326A/es unknown
- 2011-12-28 CO CO11179622A patent/CO6480962A2/es not_active Application Discontinuation
-
2012
- 2012-01-09 EC ECSP12011584 patent/ECSP12011584A/es unknown
-
2015
- 2015-06-23 IL IL239604A patent/IL239604A/en not_active IP Right Cessation
- 2015-12-30 HK HK15112838.4A patent/HK1211961A1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012530496A5 (ja) | ||
| US10465014B2 (en) | PDL-1 antibody, pharmaceutical composition thereof, and uses thereof | |
| CN109608544B (zh) | Pd-l1抗体、其抗原结合片段及其医药用途 | |
| JP2016512551A5 (ja) | ||
| JP2017052784A5 (ja) | ||
| JP2011046732A5 (ja) | ||
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| JP2016536020A5 (ja) | ||
| JP2018503380A5 (ja) | ||
| JP2012525829A5 (ja) | ||
| JP2013529059A5 (ja) | ||
| RU2011150916A (ru) | Антитела против vegf и их применения | |
| JP2016505546A5 (ja) | ||
| JP2014526898A5 (ja) | ||
| JP2014503209A5 (ja) | ||
| JP2010526028A5 (ja) | ||
| JP2018510617A5 (ja) | ||
| JP2020514277A5 (ja) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2010509931A5 (ja) | ||
| EA039946B1 (ru) | Антитела-антагонисты к интерферону альфа и интерферону омега | |
| CA3029977A1 (en) | Antibodies with low immunogenicity and uses thereof | |
| JP2022527935A (ja) | Ｃｄ３結合分子 | |
| CN115397852A (zh) | 工程化抗il-2抗体 |